GREY:IMVIF - Post by User
Post by
Breakthorough1on Jul 27, 2023 1:45pm
79 Views
Post# 35559968
January 13 2022
January 13 2022"We believe this study should help affirm and extend our understanding of the clinical benefit previously seen in r/r DLBCL patients in the SPiReL trial and may support the use of PD-L1 as a biomarker for MVP-S in combination with KEYTRUDA. Importantly, this is an open-label study, so we expect to review early data in the summer 2022."